Clinical Trial Update: A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation [Phase 3]

View source ↗

Summary

Phase 3 multicenter, randomized, double-masked, sham-controlled clinical trial for Leber hereditary optic neuropathy due to ND4 mutation. Sponsor: Wuhan Neuroph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Snippet

Sponsor: Wuhan Neurophth Biotechnology Limited Company | Conditions: Leber Hereditary Optic Neuropathy (LHON) | Phase 3 | Status: ACTIVE_NOT_RECRUITING